Morningside Ventures i aso nei na fa'alauiloa ai le fa'alauiloaina o le Adiso Therapeutics, ose kamupani fa'akomekolosi fa'afoma'i fa'ata'ita'i fa'ata'ita'i o lo'o fa'alauteleina se paipa o tala fou e fa'atatau i fa'ama'i mumu. Ua faatupeina e Morningside fuafuaga tau atinae a Adiso e oo mai i le taimi nei, faatasi ai ma fuafuaga e lagolago atili ai le tuputupu aʻe vave o le kamupani i luma.

O lo'o fa'atupuina e Adiso se paipa fou o molela'au laiti ma ni faiga fou e fa'atino ai ma fa'ama'i e tasi mea ola fa'aolaola (SS-LBP), tulituliloa fa'ailoga i le ulcerative colitis (UC), ma le C. difficile infection (CDI). I le faaopoopo atu i le lua Phase 1 polokalame (UC & CDI) ma le Phase 2 polokalame (UC), Adiso o loʻo atiaʻe se polokalame fou inflammasome i le vaega o suʻesuʻega lea o loʻo suʻesuʻeina muamua i le manava o le manava, ma le tele o nofoaga e mafai ona faʻaogaina i le lumanaʻi.

O le kamupani e aofia ai le 25 tagata faigaluega oe na muamua, i lalo o le faamalu o le Morningside, na tatalaina ma le manuia le tolu Investigational New Drug (INDs) ma ua latou failaina le tele o pateni faapea foi ma le mauaina o le US FDA Fast Track Designation, ma iu ai i le faavaeina o Adiso. Adiso o le a galue i lalo o le taʻitaʻiga a le Ofisa Sili o Pulega talu ai nei tofia, Scott Megaffin. O Mr. Megaffin e sili atu i le 30 tausaga o le poto masani fa'apisinisi ma se fa'amaumauga manuia i tulaga ta'ita'i sinia i Bristol-Myers Squibb, Pfizer, Schering-Plough, Adolor, Onconova, ma Churchill. Talu ai nei lava, na galue ai Mr. Megaffin o le Pule Sili o Adastra Pharmaceuticals, o se kamupani oncology clinical-stage development company, lea na ia taʻitaʻia ai le kamupani i se fefaʻatauaiga manuia ma Cothera Bioscience ia Oketopa 2021.

"O loʻo iai manaʻoga faʻapitoa faʻafomaʻi e leʻi faʻataunuʻuina mo togafitiga fou e faʻatatau i le faʻavaeina o le biology o faʻamaʻi inflammatory e aunoa ma le mafua ai o le immunosuppression," o le tala lea a Jason Dinges, Morningside Technology Advisory ma Adiso Board Member. "O Adiso o loʻo tamoʻe mai le faitotoʻa ma ni polokalame faʻapitoa e tolu mo le togafitiga o le ulcerative colitis ma le puipuia o le CDI faifaipea. Matou te talitonu i lalo o le taʻitaʻiga a Scott ma faʻatasi ai ma se vaega sili ona talenia o tagata atiaʻe vailaʻau, ua sauni Adiso mo le manuia.

"I Adiso o loʻo matou foʻia faʻamaʻi faʻamaʻi i auala eseese ma se auala malosi. Matou te vaʻavaʻai i se mea fou mo tagata mamaʻi, faʻaaogaina le alualu i luma lauiloa o togafitiga faʻamaʻi lea e folafola mai e toe faʻaleleia le puipuiga o le tagata talimalo, ina ia le faʻamalosia le faʻamaʻi o loʻo aʻafia pe leai foi le tagata maʻi e faʻaleagaina, "o le tala lea a Scott Megaffin, Pule Sili o Adiso Therapeutics . "Ua faʻamamaluina aʻu i le taʻitaʻia o se 'au faʻapitoa, lalolagi-vasega, ma tuʻufaʻatasia i Adiso i le atinaʻeina o nei togafitiga tulaga ese ua fuafuaina e taofi tonu ai le dysregulation e mafua mai i le mumū."

Mustafa A. Noor, MD, FACP ua auai foi i le au taʻitaʻi Adiso. O Dr. Noor na te tauaveina le tulaga o le Ofisa Sili o Fomaʻi, aumaia le sili atu i le 20 tausaga o tomai faʻapitoa i le atinaʻeina o vailaʻau i le tele o vailaʻau faʻapitoa i le tele o le amataga i le ogatotonu o le tulaga ma kamupani faʻavaomalo e aofia ai AMAG Pharmaceuticals, Akcea Therapeutics, Ipsen, Pfizer, Glaxo-Smith Kline , ma Bristol Myers Squibb.

"O le faʻamaʻi pipisi e totonugalemu i le tele o faʻamaʻi ogaoga ma o le faʻaleagaina e mafua ai le faʻaleagaina o le soifua maloloina ma le soifua manuia o tagata mamaʻi. O togafitiga o loʻo i ai nei e le lava e taofia ai le faʻalauteleina o faʻamaʻi ma faʻaleleia le lelei o le olaga i se auala saogalemu ma anoa, "o le tala lea a Dr. Noor, CMO o Adiso Therapeutics. "O uiga tulaga ese o le Adiso portfolio mo le togafitia o faʻamaʻi faʻamaʻi e mafai ona avea mulimuli ane ma vailaʻau taua mo tagata mamaʻi. Fausia i luga o suʻesuʻega faʻapitoa faʻapitoa ma vave suʻesuʻega faʻapitoa e oʻo mai i le taimi nei, ou te tulimatai atu e taʻitaʻia le isi laasaga o le atinaʻeina o falemaʻi o la matou faila faʻatasi ma se 'au poto masani o atinaʻe falemaʻi.

OA MEA E AVEA MAI LENEI TUSI:

We envision a new reality for patients, leveraging known advances of inflammatory therapeutics which promise to recalibrate the immune system of the host, so that the underlying inflammatory disease is neither overactivated nor does the patient becoming immunocompromised,”.
Building on the successful preclinical and early clinical studies to date, I look forward to leading the next stages of clinical development of our portfolio with an experienced team of clinical developers.
CDI) and a Phase 2 program (UC), Adiso is developing a novel inflammasome program in discovery phase which is being initially explored in respiratory inflammation, with multiple future potential therapeutic areas to pursue.